Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...
TipRanks on MSN

Mereo says phase 3 Orbit, Cosmic studies do not achieve primary endpoints

Mereo BioPharma (MREO) announced results from the Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta. Neither study ...
Fierce Biotech

Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.
Rheumatology Advisor

Setrusumab Misses Primary Endpoint in Osteogenesis Imperfecta Studies

Topline data were announced from two phase 3 studies evaluating setrusumab in patients with osteogenesis imperfecta.

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates ...
Pharmabiz

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...